CHEMBL2362995 Target Snapshot

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Voltage-gated T-type calcium channel shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O95180. Start with epilepsy, then reuse UniProt O95180 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with epilepsy, then reuse UniProt O95180 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 6 linked drugs

Open source guide

Disease program

epilepsy

Voltage-gated T-type calcium channel shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with epilepsy because it currently carries approved-linked support. Linked drugs include ETHOSUXIMIDE, METHSUXIMIDE, PARAMETHADIONE, PHENSUXIMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Approved-linked Open Targets-ready proxy 6 linked drugs

Open disease block

Protein anchor

Voltage-dependent T-type calcium channel subunit alpha-1H

Review this target as Voltage-gated T-type calcium channel, mapped to UniProt O95180. ChEMBL maps the protein component as Voltage-dependent T-type calcium channel subunit alpha-1H. Sequence length is 2353 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt O95180 Protein 2353 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Voltage-gated T-type calcium channel as ChEMBL target CHEMBL2362995, mapped to UniProt O95180. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Voltage-gated T-type calcium channel

PROTEIN FAMILY · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL2362995

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

O95180

Voltage-dependent T-type calcium channel subunit alpha-1H

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether Voltage-gated T-type calcium channel is the right protein anchor across sources, using UniProt O95180 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why epilepsy is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	Voltage-gated T-type calcium channel
Target Type	PROTEIN FAMILY
Organism	Homo sapiens
UniProt	O95180

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	Voltage-dependent T-type calcium channel subunit alpha-1H
UniProt Accession	O95180
Component Type	Protein
Sequence Length	2353 aa

Voltage-dependent T-type calcium channel subunit alpha-1H

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 14, 2026, 2:05 PM KST As of · Sep 14, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as Voltage-gated T-type calcium channel, mapped to UniProt O95180. ChEMBL maps the protein component as Voltage-dependent T-type calcium channel subunit alpha-1H. Sequence length is 2353 aa.

Mapped IDO95180

Review nameVoltage-gated T-type calcium channel

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Voltage-gated T-type calcium channel shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block.

Approved-linked Approved

epilepsy

6 linked drugs · 6 direct · 6 efficacy

Linked drugETHOSUXIMIDE

Linked drugMETHSUXIMIDE

Linked drugPARAMETHADIONE

Linked drugPHENSUXIMIDE

Approved-linked Approved

Seizure

2 linked drugs · 2 direct · 2 efficacy

Linked drugETHOSUXIMIDE

Linked drugMETHSUXIMIDE

Late clinical Phase III

childhood absence epilepsy

1 linked drug · 1 direct · 1 efficacy

Linked drugETHOSUXIMIDE

Late clinical Phase III

irritable bowel syndrome

1 linked drug · 1 direct · 1 efficacy

Linked drugETHOSUXIMIDE

Clinical signal Phase II

essential tremor

2 linked drugs · 2 direct · 2 efficacy

Linked drugAPINOCALTAMIDE

Linked drugSUVECALTAMIDE

Clinical signal Phase II

complex regional pain syndrome

1 linked drug · 1 direct · 1 efficacy

Linked drugETHOSUXIMIDE

Source · ChEMBL drug mechanism + indication proxy Freshness · Sep 14, 2026, 2:05 PM KST As of · Sep 14, 2026

ChEMBL target record ↗

Review Cue

How to read disease relevance

Start review with epilepsy because it currently carries approved-linked support. Linked drugs include ETHOSUXIMIDE, METHSUXIMIDE, PARAMETHADIONE, PHENSUXIMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseepilepsy

Strongest levelApproved-linked

Block modeOpen Targets-ready proxy

Assay Mix

Activity Type Distribution

IC502.0

Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL ID	pChEMBL	Type	Value (nM)	Phase
CHEMBL1479557	5.6	IC50	2500.0	Preclinical

Distribution

pChEMBL Value Distribution

0

5.0

1

5.5

0

6.0

0

6.5

0

7.0

0

7.5

0

8.0

0

8.5

0

9.0

0

9.5

pChEMBL

Assay Landscape

2

Total Assays

1

Tested Compounds

1

Assay Types

Binding — 2 assays, 1 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
protein format	2	1	5.6

CHEMBL2362995 Target Snapshot

Research home keeps recent targets

Switch target

Frame the target before identity details

Cross-source identity

Start with the right source

Basic Information

Next Actions

UniProt Target Context

How to read this target

Disease Relevance & Evidence Level

How to read disease relevance

Activity Type Distribution

Top Inhibitors (by pChEMBL)

pChEMBL Value Distribution

Assay Landscape

Confidence Score Distribution